www.onkologiecs.cz 79 / Onkologie. 2025;19(2):76-79 / ONKOLOGIE HLAVNÍ TÉMA Role imunoterapie v léčbě metastatického uroteliálního karcinomu 10. Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single- -arm, multicentre, phase 2 trial. Lancet. 2017;389(10064):67-76. 11. Galsky MD, Hahn NM, Rosenberg J, et al. Treatment of patients with metastatic urothelial cancer „unfit“ for Cisplatin- -based chemotherapy. J Clin Oncol. 2011;29(17):2432-2438. 12. Grivas P, Grande E, Davis ID, et al. Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice. ESMO Open. 2023;8(6):102050. 13. Powles TB, Perez Valderrama B, Gupta S, et al. LBA6 EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC). Annals of Oncology. 2023;34:S1340. 14. Powles T, Valderrama BP, Gupta S, et al. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. New England Journal of Medicine. 2024;390(10):875-888. 15. Grande E, Birtle AJ, Kamat AM. Re: Thomas Powles, Begoña Pérez-Valderrama, Shilpa Gupta, et al. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. N Engl J Med 2024;390:875-888. Eur Urol. 2024;86(6):e152-e153. 16. van der Heijden MS, Sonpavde G, Powles T, et al. Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma. N Engl J Med. 2023;389(19):1778-1789. 17. Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017;18(3):312-322. 18. Powles T, Durán I, van der Heijden MS, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2018;391(10122):748-757. 19. Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909-1920. 20. Alhalabi O, Campbell M, Shah A, et al. Emerging treatments in advanced urothelial cancer. Curr Opin Oncol. 2020;32(3):232-239. 21. Kawashima A, Ishizuya Y, Yamamoto Y, et al. Recent developments and future directions of first-line systemic therapy combined with immunotherapy for advanced or metastatic urothelial carcinoma: a historical perspective on treatment evolution. Int J Clin Oncol. 2024;29(8):1096-1104. 22. Ascione CM, Napolitano F, Esposito D, et al. Role of FGFR3 in bladder cancer: Treatment landscape and future challenges. Cancer Treat Rev. 2023;115:102530. 23. Albarrán V, Rosero DI, Chamorro J, et al. Her-2 Targeted Therapy in Advanced Urothelial Cancer: From Monoclonal Antibodies to Antibody-Drug Conjugates. Int J Mol Sci. 2022;23(20). 24. Grivas P, Pouessel D, Park CH, et al. Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum- -Based Chemotherapy: TROPHY-U-01 Cohort 3. J Clin Oncol. 2024;42(12):1415-1425. 25. Hoffman-Censits J, Grivas P, Powles T, et al. The JAVELIN Bladder Medley trial: avelumab-based combinations as first- -line maintenance in advanced urothelial carcinoma. Future Oncol. 2024;20(4):179-190. VÁŠ PARTNER V ONKOUROLOGII Astellas Pharma s.r.o., Rohanské nábřeží 678/29, 186 00 Praha 8 – Karlín, www.astellas.com/cz 10/2024 | MAT-CZ-NON-2024-00011
RkJQdWJsaXNoZXIy NDA4Mjc=